Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269985 | 0.88 | CCR1 (0.56) | RAB9AMEN1KMT2AMAPTHPGD | |
| Water SCHEMBL27687531 | 0.85 | HSD11B1 (0.43) | RAB9AMEN1KMT2AMAPTHPGD | |
| SCHEMBL4900058 | 0.80 | RXRA (0.54) | DHODH | |
| SCHEMBL3697238 | 0.80 | RAB9A (0.44) | RAB9AMEN1KMT2AMAPTHPGD | |
| SCHEMBL3131891 | 0.79 | SCN9A (0.49) | HSD11B1DHODH | |
| SCHEMBL3626772 | 0.78 | CTSS (0.50) | RAB9AMEN1KMT2AMAPTHPGD | |
| SCHEMBL8775845 | 0.78 | CYP1A2 (0.47) | RAB9AMEN1KMT2AMAPTHPGD | |
| SCHEMBL4351608 | 0.78 | DHODH (0.54) | RAB9AMEN1KMT2AMAPTHPGD | |
| SCHEMBL597362 | 0.78 | PTPN5 (0.49) | RAB9AMEN1KMT2AMAPTHPGD | |
| SCHEMBL23911681 | 0.77 | MEN1 (0.72) | RAB9AMEN1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2208722-A1 | PROCESS FOR PRODUCTION OF DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALYST, PROCESS FOR PRODUCTION OF -AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE SALT | National University Corporation Nagoya University (JP) | 2010-07-21 | — | — | EP | disclosed |
| US-7423059-B2 | Pharmaceutically active compounds and methods of use | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423059-B2 | Pharmaceutically active compounds and methods of use | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423059-B2 | Pharmaceutically active compounds and methods of use | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-20050209222-A1 | Pharmaceutically active compounds and methods of use | CAMBRIDGE NEUROSCIENCE, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6756389-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030069274-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH | 2003-04-10 | — | — | US | disclosed |
| EP-0959887-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0959887-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998006401-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249431-A1 | PROCESS FOR MANUFACTURING DISULFONIC ACID COMPOUND, ASYMMETRIC MANNICH CATALST, PROCESS FOR MANUFACTURING BETA-AMINOCARBONYL DERIVATIVE, AND NOVEL DISULFONATE | MGAT2, MPST, MGAT1 | RAB9A 3592/4885MEN1 1250/4885KMT2A 53/4885 |
| US-20050209222-A1 | Pharmaceutically active compounds and methods of use | ACHE, NLN, PARK7 | RAB9A 1933/4885MEN1 1204/4885KMT2A 4129/4885 |
| US-20030069274-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | ACHE, NLN, PARK7 | RAB9A 1933/4885MEN1 1204/4885KMT2A 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.